These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
594 related articles for article (PubMed ID: 31644555)
1. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients. Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555 [TBL] [Abstract][Full Text] [Related]
2. Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies. Masutani K; Tsuchimoto A; Kurihara K; Okabe Y; Kitada H; Okumi M; Tanabe K; Nakamura M; Kitazono T; Tsuruya K; Transplantation; 2017 Jun; 101(6):1416-1422. PubMed ID: 27391195 [TBL] [Abstract][Full Text] [Related]
3. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation. Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467 [TBL] [Abstract][Full Text] [Related]
4. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment. Okada M; Watarai Y; Iwasaki K; Murotani K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Morozumi K; Uchida K; Kobayashi T Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635 [TBL] [Abstract][Full Text] [Related]
5. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498 [TBL] [Abstract][Full Text] [Related]
6. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation. Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M; Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant. Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532 [TBL] [Abstract][Full Text] [Related]
8. Individualized Preconditioning for ABO-Incompatible Living-Donor Kidney Transplantation: An Initial Report of 48 Cases from China. Wang XD; Liu JP; Fan Y; Song TR; Shi YY; Li YM; Lv YH; Li XH; Huang ZL; Lin T Ann Transplant; 2020 Feb; 25():e920224. PubMed ID: 32029699 [TBL] [Abstract][Full Text] [Related]
9. Lower incidence of de novo donor-specific antibodies against HLA-DR in ABO-incompatible renal transplantation. Okada M; Watarai Y; Iwasaki K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Kobayashi T Hum Immunol; 2019 Mar; 80(3):169-175. PubMed ID: 30552908 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation. Sugiyama K; Hyodo Y; Aikawa A Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258 [TBL] [Abstract][Full Text] [Related]
12. Once-daily vs twice-daily tacrolimus for de novo living kidney transplantation patients including ABO/HLA compatible and incompatible: A randomized trial. Okumi M; Unagami K; Furusawa M; Kakuta Y; IIzuka J; Takagi T; Shirakawa H; Shimizu T; Omoto K; Inui M; Ishida H; Tanabe K Clin Transplant; 2018 Dec; 32(12):e13423. PubMed ID: 30318624 [TBL] [Abstract][Full Text] [Related]
13. De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation. Koch M; Wiech T; Marget M; Peine S; Thude H; Achilles EG; Fischer L; Lehnhardt A; Thaiss F; Nashan B Clin Transplant; 2015 Nov; 29(11):1021-8. PubMed ID: 26333844 [TBL] [Abstract][Full Text] [Related]
14. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience. Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457 [TBL] [Abstract][Full Text] [Related]
15. Analysis of predictive and preventive factors for de novo DSA in kidney transplant recipients. Hirai T; Furusawa M; Omoto K; Ishida H; Tanabe K Transplantation; 2014 Aug; 98(4):443-50. PubMed ID: 24717219 [TBL] [Abstract][Full Text] [Related]
16. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients. Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587 [TBL] [Abstract][Full Text] [Related]
17. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413 [TBL] [Abstract][Full Text] [Related]
18. ABO-incompatible kidney transplantation: first cases in Turkey. Tuncer M; Yücetin L; Tekin S; Demirbas A Transplant Proc; 2012; 44(6):1703-5. PubMed ID: 22841248 [TBL] [Abstract][Full Text] [Related]
19. Single cohort study: ABO-incompatible kidney transplant recipients have a higher risk of lymphocele formation. Jänigen BM; Salabè C; Glatz T; Thomusch O; Lässle C; Fichtner-Feigl S; Zschiedrich S; Pisarski P Langenbecks Arch Surg; 2019 Dec; 404(8):999-1007. PubMed ID: 31456076 [TBL] [Abstract][Full Text] [Related]
20. Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation. Ishida H; Kondo T; Shimizu T; Nozaki T; Tanabe K Transpl Int; 2015 Mar; 28(3):286-96. PubMed ID: 25363583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]